Bayer AG
Operates as a diversified life science company providing prescription and over-the-counter pharmaceuticals, consumer health products, and crop protection solutions globally.
As of Oct 16, 2026
Summary
Bayer AG is a German pharmaceuticals and life sciences company with a market capitalisation of €43.6 billion. The stock is trading at €44.46 with a bearish technical lean despite a substantial one-year return of 66.3%, though momentum has reversed sharply over the past month, down 9.3%.
Price history
As of Oct 16, 2026
Performance
+0.11%
+1.58%
-9.34%
-6.64%
+20.47%
+66.28%
As of Oct 16, 2026
Technical indicators
- 40.3
- -0.09Bearish
- 50: 47.76 · 200: 43.3
- €42.56 / €49.45
Technical Bias
Bearish lean
Bayer AG's technical setup currently leans bearish. The MACD has turned negative at -0.09, which is the primary directional signal, whilst the RSI at 40.3 and moving average structure remain neutral—the stock sits between its 50-day average (€47.76) and 200-day average (€43.30). Support sits at €42.56 and resistance at €49.45, with the current price at €44.46. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Oct 16, 2026
Fundamentals
- €43.6B
- —
- €-1.80
- -3.83%
- +1.2%
- €2.08B
- 0.84
- €25.71 – €53.92
- 0.25%
- Apr 27, 2026
- Nov 3, 2026 (16 days)
As of Oct 18, 2026
Upcoming catalysts
- Earnings report
As of Oct 18, 2026
Latest news
As of Oct 18, 2026
MonkeyTrade's Take on Bayer AG
Short-term outlook
The technical setup leans bearish but not decisively: MACD is negative and the stock is down 9.3% over the past month, though RSI at 40.3 sits in neutral territory rather than oversold extremes. Bayer trades between its 50-day average of €47.76 and 200-day average of €43.3, with €42.56 support the key line to watch, a break below which would confirm further downside, while a reclaim of €49.45 resistance would challenge the bearish read. No earnings catalyst is imminent, with the next report not due until November 2026.
Medium-term outlook
Bayer's fundamentals are weak for the medium term: revenue growth is barely positive at +1.2%, the company is posting a negative profit margin of -3.8%, and the dividend yield has shrunk to just +0.3%, leaving little cushion for investors. With the technical lean also bearish, the balance of evidence points downward over the next few quarters. A clear swing back to positive profit margins would be the key development needed to change this view.
Key risks
- Bayer's profit margin sits at -3.8%, signalling the company is currently operating at a loss rather than generating returns from its revenue base.
- Revenue growth of just +1.2% year-on-year is modest, suggesting limited top-line momentum to offset profitability pressures.
- The stock trades at €44.46, well off its 52-week high of €53.92, reflecting how far sentiment has pulled back even with the current share price still above the 52-week low of €25.71.
- Pipeline-dependent news flow, such as the FDA acceptance for the CKD filing, means near-term regulatory and clinical outcomes can meaningfully sway the stock given the company's current lack of profitability.
About Bayer AG
Bayer AG is a German healthcare company listed on XETRA under the ticker BAYN, operating in the drug manufacturers – general industry. With a market capitalisation of €43.6 billion, Bayer sits among the larger names in European healthcare, reflecting its broad footprint across pharmaceuticals and related health products. Its scale points to a business with established operations rather than an early-stage or niche player.
Looking at the key figures, Bayer currently shows no reported price-to-earnings ratio, meaning that particular earnings-based valuation measure isn't available from the data at hand. The dividend yield stands at +0.3%, a modest return to shareholders through payouts. Together, these figures give a partial snapshot of Bayer's current financial profile within the healthcare sector, useful as a starting point for anyone researching the stock further.
How to trade Bayer AG
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.